Post-Induction Outcomes and Updated Minimal Residual Disease Analysis from GMMG-HD10/DSMM-XX (MajesTEC-5): A Study of Teclistamab-Based Induction Regimens in Newly Diagnosed Multiple Myeloma (NDMM)

IF 2.7 4区医学 Q2 HEMATOLOGY

Clinical Lymphoma, Myeloma & Leukemia Pub Date : 2025-09-01 DOI:10.1016/S2152-2650(25)03417-2

Marc Raab, Niels Weinhold, K. Martin Kortüm, Jan Krönke, Lilli Podola, Uta Bertsch, Julia Mersi, Stefanie Huhn, Michael Hundemer, Roland Fenk, Katja Weisel, Alexander Brobeil, Elias Mai, Natalie Schub, Florian Bassermann, Monika Engelhardt Florian Bassermann, Mathias Hänel, Hans Salwender, Raphael Teipel, Mohamed Amine Bayar, Leo Rasche

引用次数: 0

查看原文本刊更多论文

GMMG-HD10/DSMM-XX （MajesTEC-5）诱导后结果和最新的最小残留疾病分析：新诊断的多发性骨髓瘤（NDMM）中基于替司他抗的诱导方案的研究

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical Lymphoma, Myeloma & Leukemia ONCOLOGY-HEMATOLOGY

CiteScore

2.70

自引率

3.70%

发文量

1606

审稿时长

26 days

期刊介绍： Clinical Lymphoma, Myeloma & Leukemia is a peer-reviewed monthly journal that publishes original articles describing various aspects of clinical and translational research of lymphoma, myeloma and leukemia. Clinical Lymphoma, Myeloma & Leukemia is devoted to articles on detection, diagnosis, prevention, and treatment of lymphoma, myeloma, leukemia and related disorders including macroglobulinemia, amyloidosis, and plasma-cell dyscrasias. The main emphasis is on recent scientific developments in all areas related to lymphoma, myeloma and leukemia. Specific areas of interest include clinical research and mechanistic approaches; drug sensitivity and resistance; gene and antisense therapy; pathology, markers, and prognostic indicators; chemoprevention strategies; multimodality therapy; and integration of various approaches.